Avoro Capital Advisors Reduces Its Stake in BPMC ($BPMC)

Avoro Capital Advisors has sold its entire stake in BPMC, totaling 375,000 shares.

Written by Trueearnings · Published Jun 13, 2026, 5:36 AM EDT · Updated Jun 14, 2026, 4:55 AM EDT

Key Points

Avoro Capital Advisors sold all 375,000 shares of BPMC, fully exiting its position as reported on November 14, 2025.
Insiders at BPMC, including the President of R&D, sold shares on July 17, 2025, with notable transactions by multiple executives.
Analysts have set new price targets for BPMC, with several firms maintaining a 'hold' rating and target prices around $129.

Avoro Capital Advisors has completely exited its position in BPMC, selling all 375,000 shares it previously held. This move was disclosed in the latest Form 13F filing with the SEC, reflecting the fund's holdings as of the most recent reporting period.

What Changed in Avoro Capital Advisors' BPMC Position

Avoro Capital Advisors slashed its BPMC holdings by 375,000 shares, leaving it with no shares in the company. This represents a 100% reduction from its previous stake, signaling a full exit from the investment.

Other Institutional Activity in BPMC

While Avoro Capital Advisors exited its position, other funds have maintained or reduced their holdings in BPMC. Kelleher Financial Advisors held steady with 300 shares valued at about $38,454. MassMutual Private Wealth & Trust, FSB, also kept its position unchanged with 9 shares. Keating Financial Advisory Services, Inc. held 4 shares without any change. Huntington National Bank maintained a single share valued at $129. Meanwhile, DekaBank Deutsche Girozentrale also exited, reducing its stake by 25,883 shares to zero.

Insider Buying and Selling at BPMC

Several insiders at BPMC sold shares on July 17, 2025. Fouad Namouni, President of R&D, sold 83,281 shares. Other executives, including John Tsai, Lynn Seely, Daniella Beckman, and Debra Durso-Bumpus, also engaged in selling activities, with Beckman selling a total of 14,744 shares across two transactions.

Analysts Set New Price Targets

Analysts have been active in updating their ratings for BPMC. On June 17, 2025, Wells Fargo downgraded the stock to a 'hold' with a price target of $129. Morgan Stanley and UBS maintained their 'hold' ratings with the same target. Citigroup upgraded its rating to 'hold' with a target of $129 on June 4. Other firms like Stephens & Co., Scotiabank, Wedbush, and Needham also set their targets around $129 to $135, maintaining a cautious outlook.

Bottom Line

Avoro Capital Advisors' decision to sell its entire stake in BPMC is a notable development in the company's institutional ownership landscape. Investors often track such moves for insights into market sentiment, though it's important to remember that 13F filings are backward-looking and may not reflect current positions. Meanwhile, insider sales and analyst ratings provide additional context on BPMC's market perception.